.gif) |
2016
Cancer Vaccines: Are They the Wave of the Future? : Oncology Times http://bit.ly/2blp13O
Types and challenges described
|
|
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences
The results suggest that bivalency and foreign sequences combine to increase the efficiency of chemokine-Id DNA vaccines.
|
|
Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses Despite Profound Immunosuppression cancerres.aacrjournals.org
Of 17 evaluable patients, five developed specific anti-vaccine antibodies, and eight developed anti-Fab T-cell responses. T-cell reactivity was independent of the cellular immune status and was idiotype specific as shown by statistical regression analysis (P = 0.0024) and epitope mapping studies. Intradermal administration of uncoupled recombinant idiotype with appropriate adjuvants may overcome profound clinical immunosuppression and induce specific immune responses.
|
|
A novel proteoliposomal vaccine induces antitumor immunity against
follicular lymphoma - bloodjournal.hematology
Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component
derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific. ~ Patent information pharmcast.com
|
|
Custom-Made Lymphoma Vaccine Promising - webmd.com 9-2006
Vaccine Made From Patient's Own Tumor Cells Teaches Immune System to Fight Cancer
|
|
FDA Gives Permission to Use Very Sensitive Molecular Evidence of
Cancer in BiovaxID Pivotal Phase 3 Clinical Trial - biz.yahoo.com
|
|
In vivo disruption of tolerogenic [tolerance producing] cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr 1;107(7):2871-8. Epub 2005 Dec 8. PMID: 16339406 | Related articles
|
|
BiovaxID™ Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial. Session Type: Poster Session 645-II
|
|
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
Blood. 2006 Jan 15;107(2):628-36. Epub 2005 Sep 22. PMID: 16179369 | Related articles
|
|
Favrille Completes FavId Enrollment - thestreet.com
|
|
BiovaxID™ Promising for Follicular Lymphoma - cancerconsultants.com
For patients who were in remission following PACE chemotherapy after 6 months and received BiovaxID vaccine: At a median follow-up of 9.2 years - 45% of patients remained in remission, overall survival rate is 95%. The median cancer-free survival was 8 years.
|
|
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Cancer Res. 2005 Jul 1;65(13):5958-64. PMID: 15994975 | Related articles
|
|
Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun;5(6):841-52. PMID: 15952914 | Related articles
|
|
Vaccine Therapy for Non-Hodgkin's Lymphoma: An Interview With Joseph M. Connors, MD Hematology-Oncology 7(1), 2004. © 2004 Medscape (free login req.) 01/09/2004
|
|
Idiotype Vaccine Following EPOCH-Rituximab Treatment in Untreated Mantle Cell Lymphoma. Wyndham H. Wilson, et al Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
- abstracts-on-line.com
|
|
Feasibility of idiotype vaccination was statistically compared among five different B-cell malignancies in first relapse. When based on hybridoma production techniques, idiotypic vaccination for relapsed B-cell malignancies was consistently feasible only in follicular lymphoma patients, whereas the main cause of failure in other settings was the short survival of idiotype-producing hybridomas. - haematologica.it
|
|
ASCO 2003 - Oncophage (for indolent fNHL) in the Phase II trial, there were responses observed ... suggesting the potential utility of the vaccine in patients with minimal residual disease. BusWire
|
|
Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma - Haematologica 2002 Apr;87(4):400-7 abstract - NIH.gov
|
|
Biovest Cancer Vaccine -- Overview of Vaccine Results - accentia.net
|
|
CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol. 2000 Dec;30(12):3591-7. - PubMed | Related abstracts
|
|
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Cancer Res. 2002 Oct 15;62(20):5845-52. PMID: 12384547 - PubMed
|
|
Vaccine Therapies for Non-Hodgkin's Lymphoma. Current Treat Options Oncol. 2002 Aug;3(4):307-15.
PMID: 12074767 - PubMed
|
TOPIC SEARCH: PubMed: Treatment | Review | Dendritic | Idiotype | DNA type | Heat Shock type